Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of NBP608 vs Varivax in Healthy Children
NCT03114982Phase 2Completed
- Sponsor
- SK Chemicals
- Start
- May 2016
- Primary completion
- Jul 2016
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NBP608 in varicella (VZV) (4 arms), sponsored by SK Chemicals. Primary endpoint: Seroconversion rate measured by FAMA (Fluorescent Antibody to Membrane Antigen) assay at 6 weeks. Started May 2016; status: completed.
02
Drugs
NBP608
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT03114982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114982.